SCHEMBL6850893

SCHEMBL6850893

O=C(CC1CCCCC1)NC1CCc2[nH]cnc2C1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
HPGD P15428 2/20 0.49
EPHX1 P07099 1/20 0.49
MEN1 O00255 1/20 0.41
ALPL P05186 1/20 0.41
POLB P06746 1/20 0.41
P2RX7 Q99572 2/20 0.38
RECQL P46063 1/20 0.38
EPHX2 P34913 2/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NAMPT P43490 1/20 0.35
MTNR1A P48039 2/20 0.35
MTNR1B P49286 2/20 0.35
AAK1 Q2M2I8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6849668 0.88 HPGD (0.51) KMT2AHPGDMEN1ALPLPOLB
SCHEMBL6851100 0.79 MEN1 (0.36) KMT2AHPGDMEN1ALPLPOLB
SCHEMBL6851284 0.78 RAB9A (0.51) KMT2AHPGDMEN1P2RX7RECQL
SCHEMBL6849680 0.76 LMNA (0.56) KMT2AHPGDPOLBP2RX7EPHX2
SCHEMBL7099342 0.74 JAK3 (0.39)
SCHEMBL6846858 0.74 LMNA (0.43) KMT2AHPGDEPHX1MEN1POLB
SCHEMBL26399136 0.73 LMNA (0.42) HPGDEPHX1EPHX2NPC1RAB9A
SCHEMBL7094424 0.72 MTNR1A (0.49) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL6846909 0.72 LMNA (0.45) HPGDEPHX1POLBEPHX2MTNR1A
Hydrochloric Acid SCHEMBL7096357 0.71 LMNA (0.44) HPGDEPHX1POLBEPHX2MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
EP-1268484-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed
WO-2001068652-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 KMT2A 300/4885HPGD 283/4885EPHX1 628/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 KMT2A 300/4885HPGD 283/4885EPHX1 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.